Marrow mesenchymal stem cell mediates diabetic nephropathy progression via modulation of Smad2/3/WTAP/m6A/ENO1 axis

Abstract

AbstractDiabetic nephropathy (DN) is one of the common microvascular complications in diabetic patients. Marrow mesenchymal stem cells (MSCs) have attracted attention in DN therapy but the underlying mechanism remains unclear. Here, we show that MSC administration alleviates high glucose (HG)‐induced human kidney tubular epithelial cell (HK‐2 cell) injury and ameliorates renal injury in DN mice. We identify that Smad2/3 is responsible for MSCs‐regulated DN progression. The activity of Smad2/3 was predominantly upregulated in HG‐induced HK‐2 cell and DN mice and suppressed with MSC administration. Activation of Smad2/3 via transforming growth factor‐β1 (TGF‐β1) administration abrogates the protective effect of MSCs on HG‐induced HK‐2 cell injury and renal injury of DN mice. Smad2/3 has been reported to interact with methyltransferase of N6‐methyladenosine (m6A) complex and we found a methyltransferase, Wilms' tumor 1‐associating protein (WTAP), is involved in MSCs‐Smad2/3‐regulated DN development. Moreover, WTAP overexpression abrogates the improvement of MSCs on HG‐induced HK‐2 cell injury and renal injury of DN mice. Subsequently, α‐enolase (ENO1) is the downstream target of WTAP‐mediated m6A modification and contributes to the MSCs‐mediated regulation. Collectively, these findings reveal a molecular mechanism in DN progression and indicate that Smad2/3/WTAP/ENO1 may present a target for MSCs‐mediated DN therapy.